Publicaciones (30) Publicaciones en las que ha participado algún/a investigador/a

2022

  1. A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα and IL-1β

    Cancer Discovery, Vol. 12, Núm. 9, pp. 2140-2157

  2. Advances in mRNA-based drug discovery in cancer immunotherapy

    Expert Opinion on Drug Discovery, Vol. 17, Núm. 1, pp. 41-53

  3. Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer

    Journal for immunotherapy of cancer, Vol. 10, Núm. 12

  4. C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d

    Frontiers in Immunology, Vol. 13

  5. CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

    Science Advances, Vol. 8, Núm. 39

  6. Cancer vaccines: the next immunotherapy frontier

    Nature Cancer, Vol. 3, Núm. 8, pp. 911-926

  7. Central Role of the Antigen-Presentation and Interferon-γ Pathways in Resistance to Immune Checkpoint Blockade

    Annual Review of Cancer Biology, Vol. 6, pp. 85-102

  8. Charting roadmaps towards novel and safe synergistic immunotherapy combinations

    Nature Cancer, Vol. 3, Núm. 6, pp. 665-680

  9. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781

  10. DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity

    The Journal of experimental medicine, Vol. 219, Núm. 12

  11. Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy

    Cancer research, Vol. 82, Núm. 23, pp. 4373-4385

  12. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology

    Blood Advances, Vol. 6, Núm. 2, pp. 690-703

  13. Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness

    Frontiers in Cell and Developmental Biology, Vol. 10

  14. Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 65-122

  15. Neutrophil Extracellular Traps, Local IL-8 Expression, and Cytotoxic T-Lymphocyte Response in the Lungs of Patients With Fatal COVID-19

    Chest, Vol. 162, Núm. 5, pp. 1006-1016

  16. Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity

    Cells, Vol. 11, Núm. 19

  17. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

    The Lancet Oncology, Vol. 23, Núm. 1, pp. 77-90

  18. Novel strategies exploiting interleukin-12 in cancer immunotherapy

    Pharmacology and Therapeutics, Vol. 239

  19. Omentum: Friend or foe in ovarian cancer immunotherapy?

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 117-131

  20. Overcoming the limitations of cytokines to improve cancer therapy

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 107-141